Literature DB >> 2908714

Calcium antagonists--adverse drug interactions.

H Reicher-Reiss1, H N Neufeld, F X Ebner.   

Abstract

In the clinical management of heart disease, calcium channel blockers are generally prescribed in combination with one or more anti-angina, antiarrhythmic, or antihypertensive agents. Two different mechanisms are involved in drug interactions: pharmacokinetic and pharmacodynamic. In the former, the disposition of one drug is altered by the action of another, causing an increase or decrease in its absorption or its modified distribution, metabolism, or excretion. In pharmacodynamic interactions, the physiologic effects of one drug interfere either directly or indirectly with those of another, for instance, by alterations in fluid or electrolyte balance. This effect may be antagonistic or additive. The present work outlines the possible adverse interactions between the three main calcium antagonists and other therapeutic agents, including digoxin, beta blockers and antiarrhythmic, anesthetic, antihypertensive, antiasthmatic, and antidiabetic drugs and contrast media. Knowledge of these effects is of major clinical importance in the treatment of cardiac patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2908714     DOI: 10.1007/BF02209082

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  36 in total

1.  Digoxin plasma concentrations and nifedipine.

Authors:  G G Belz; P E Aust; R Munkes
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

2.  Decreased serum lithium during verapamil therapy.

Authors:  L A Weinrauch; S Belok; J A D'Elia
Journal:  Am Heart J       Date:  1984-11       Impact factor: 4.749

3.  Clinical pharmacology. Adverse drug interactions.

Authors:  J K Aronson; D G Grahame-Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-24

4.  Interaction between verapamil and contrast media in coronary arteriography: comparison of standard ionic and new nonionic media.

Authors:  C B Higgins; M Kuber; R A Slutsky
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

Review 5.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

6.  Disopyramide in myocardial infarction.

Authors:  D Ross; J Vohra; J G Sloman
Journal:  Lancet       Date:  1978-02-11       Impact factor: 79.321

7.  Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease.

Authors:  C Y Chew; H S Hecht; J T Collett; R G McAllister; B N Singh
Journal:  Am J Cardiol       Date:  1981-04       Impact factor: 2.778

8.  Detrimental effect of propranolol in patients with coronary arterial spasm countered by combination with diltiazem.

Authors:  P Y Tilmant; J M Lablanche; F A Thieuleux; B A Dupuis; M E Bertrand
Journal:  Am J Cardiol       Date:  1983-08       Impact factor: 2.778

9.  Nifedipine enhances the bronchodilator effect of salbutamol.

Authors:  A M Lever; P A Corris; G J Gibson
Journal:  Thorax       Date:  1984-08       Impact factor: 9.139

10.  Influence of cimetidine on verapamil kinetics and dynamics.

Authors:  M S Smith; M C Benyunes; T D Bjornsson; D G Shand; E L Pritchett
Journal:  Clin Pharmacol Ther       Date:  1984-10       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.